Loading stock data…
Artelo Biosciences, Inc. (ARTL)
$1.02-0.04 (-3.77%)
Market ClosedLast close Jul 24
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Artelo Biosciences, Inc. in the Healthcare sector is trading at $1.02 with a market capitalization of $5M. The stock is currently near its 52-week low of $0.96, remaining 77.9% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.69M↑ | -$2.79M↑ | -$3.09M↑ | -$3.15M↓ | -$2.38M |
| Net Income | -$2.96M↑ | -$4.17M↓ | -$3.12M↑ | -$3.22M↓ | -$2.37M |
Peer Comparison
JNJUNHPFE
Fundamentals
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual can...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-201.81%
Volume
Today's trading volume
63,002
Recent News
BC-Most Active Stocks
Megan Holdings Ltd. 7,893,938 0.2401
Artelo Biosciences announces 3-for-1 reverse stock split
Artelo Biosciences (ARTL) announced that on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split of the Company’s common stock. The Company’s common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, March 10, 2026. The Board of Directors determined the 3-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to improve its marketability and liquidity. Claim 70% Off T
Alphabet downgraded, Boeing upgraded: Wall Street's top analyst calls
Alphabet downgraded, Boeing upgraded: Wall Street's top analyst calls
Wall Street Weighs Payrolls, Jobless Claims Data, Driving Muted Premarket Action for US Equity Futures
US equity futures were flat ahead of Thursday's opening bell as traders assessed economic data, incl